BML, INC. (4694) Stock Price

BML operates a diverse range of businesses centered on clinical laboratory testing. Its main business segments include clinical laboratory testing, food and hygiene testing, clinical trial support, and manufacturing of laboratory containers. These operations are conducted through consolidated subsidiaries and affiliated companies.

BML's consolidated subsidiaries include PCL Japan, Japan Clinical Services, Allegro, and BML Food Science. These companies handle laboratory testing services for regional hospitals and clinics, as well as food and hygiene testing and clinical trial support operations.

BML utilizes IT systems to process test data and report results to customers promptly. This enables efficient operations and high-quality service delivery. Additionally, test results are used as billing data for customers and are linked to automatic revenue recognition.

Japan Clinical Services handles specimen reception, test information reporting, and transportation for BML's clinical laboratory testing. This supports operational efficiency and rapid service delivery.

PCL Japan and Tokai Cell Research Institute subcontract pathology and cytology testing from BML. DPR similarly subcontracts these tests from Morioka Clinical Laboratory Center, providing specialized testing services.

BML Food Science subcontracts food and hygiene testing from the foodservice industry and large retailers, and also provides consulting services. BML addresses diverse customer needs by subcontracting these tests.

Allegro subcontracts clinical trial implementation support services from pharmaceutical companies. BML Life Science Holdings provides management guidance to BML Food Science and Allegro, supporting business development.

BML Medical Works manufactures laboratory containers. This ensures stable supply of materials necessary for BML's testing operations and supports smooth business operations.

Kyushu Open Laboratories provides management guidance to Biken, Labotech, and QCL. This supports operational management at each company and promotes growth across the group.

BML's core strategy is to provide rapid and highly accurate testing services, with clinical laboratory testing as its primary business. By accurately identifying market needs and adopting cutting-edge technology, the company offers over 4,000 test items. This approach aims to create a culture of improved health and wellness.

The company pursues sustainable growth and enhanced corporate value by continuously improving quality and productivity. As healthcare system reforms advance, there is growing demand for greater efficiency and quality in medical services. BML is committed to responding flexibly to these changes and becoming a company that contributes to the digitalization of healthcare.

The Ninth Medium-Term Management Plan, beginning in fiscal 2024, pursues "enhanced quality," "solutions," and "mutual development," with business expansion goals extending ten years ahead. The company will implement six core strategies centered on next-generation laboratory construction, including sales and market share expansion and improved profitability.

BML is improving customer experience value and operational efficiency through DX solutions. The company plans approximately 10 billion yen in DX promotion investments and is actively developing digital talent. Additionally, the company is strengthening its ESG initiatives across environmental, social, and governance areas.

BML promotes management with awareness of capital costs, targeting ROE of 8.0% or higher. Through investments in next-generation laboratory construction and DX, the company aims to improve profitability and enhance shareholder returns. These efforts are designed to achieve sustainable growth and increase corporate value.